Calming microglia: a future method for treating multiple sclerosis Jarred Younger, PhD University of Alabama at Birmingham
|
|
|
- Joel Briggs
- 7 years ago
- Views:
Transcription
1 Calming microglia: a future method for treating multiple sclerosis Jarred Younger, PhD University of Alabama at Birmingham Sonja Paetau, University of Helsinki
2 Disclosures Will be discussing off-label use of medications Will refer only to published scientific data No conflicts of interest
3 Overview Pathophysiology of MS Actions of LDN in MS Previous clinical trials of LDN Future clinical research of LDN Future clinical use of LDN
4 Overview Pathophysiology of MS Actions of LDN in MS Previous clinical trials of LDN Future clinical research of LDN Future clinical use of LDN
5 Overview of MS Siemens
6 Progression of MS First episode RRMS SPMS
7 Pathophysiology of MS Torres-Platas et al., 2014, J Neuroinflammation
8 Central immune contribution Ehrlich E & Mattiuz K QIAGEN, sabiosciences.com
9 Degradation of blood brain barrier Vishnu et al., 2014; Nat Rev Neuro
10 Peripheral immune contribution Miller et al., 2007; Nat Rev Immunol
11 Overview Pathophysiology of MS Actions of LDN in MS Previous clinical trials of LDN Future clinical research of LDN Future clinical use of LDN
12 The Promise promise of of LDN LDN Politis et al., 2012, Frontiers in Pharmacology
13 LDN animal testing Rahn et al., 2011; Brain Res
14 Central immune-modulating effects of LDN Liu, B et al. 2000, JPET
15 Peripheral immune-modulating effects of LDN Duffy et al., 2014; MS Inter
16 Overview Pathophysiology of MS Actions of LDN in MS Previous clinical trials of LDN Future clinical research of LDN Future clinical use of LDN
17 LDN and MS clinical trials to-date Size Length Type Outcome Gironi et al., weeks Primary Progressive Reduction of spasticity Cree et al., weeks Relapsing-Remitting or Secondary Progressive No efficacy Sharafaddinzadeh et al., weeks Mixed Improvement mental scores Gironi M, Martinelli-Boneschi, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M Franchi S, Martinelli V, Nemni R, Comi G, Martino G. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008, 14: Cree B, Kornyeyeva E, Goodin D. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 2010, 68: 145. Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010, 16: 964.
18 Problems with previous clinical trials Not of long enough duration Varying diagnostic criteria Varying outcomes
19 2015 Chart Review N = mg LDN Average Tx duration = 804 days 60% reported LDN improved fatigue 60% reported LDN improved disease severity Minimal side effects Turel A, Oh K, Zagon I, McLaughlin P. Low dose naltrexone for treatment of multiple sclerosis: a retrospective chart review of safety and tolerability. J Clin Psychopharmacol 2015, 35: 609.
20 Overview Pathophysiology of MS Actions of LDN in MS Previous clinical trials of LDN Future clinical research of LDN Future clinical use of LDN
21 Major goals of future clinical trials Need to be of much longer duration Need to use same outcomes as major trials Need to comprehensively assess outcomes Need to involve radiologic scans Need to target early forms of condition Need larger sample sizes Need to frequently assess outcomes Need to do dosage-finding studies
22 Overview Pathophysiology of MS Actions of LDN in MS Previous clinical trials of LDN Future clinical research of LDN Future clinical use of LDN
23 Using LDN early in disease course Teva
24 Adjustments of use of LDN Dosage Timing Mode of administration
25 Future treatments based on LDN Naltrexone analogs Other microglia modulators Botanicals
26 References Sonja Paetau, Torres-Plates S et al., Morphometric characterization of microglial phenotypes in human cerebral cortex, J Neuroinflammation 2014, 11 Ehrlich E & Mattiuz K, Inflammation and neurodegenerative disease: a role of the estrogen receptor in suppression of inflammation in the brain Vishnu AC, Robel S, Watkins S, Sontheimer H. A neurocentric perspective on glioma invasion. Nature Reviews Neuroscience 2014, 15: 455. Miller S, Turley D, Podojil J. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease, Nat Rev Immunol 2007, 7: 665. Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol 2012, 29. Rahn K, McLaughlin P, Zagon I. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis. Brain Res 2011, 1381: 243. Liu B, Du L, Hong J. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000, 293: 607. Duffy S, Lees J, Moalem-Taylor G. The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult Scler Int Teva,
Clinical Trials for Low Dose Naltrexone
1 Customized, Patient Specific, Compounded Medications Clinical Trials for Low Dose Naltrexone Updated: Nov 10, 2008 "LDN may well be the most important therapeutic breakthrough in over fifty years. It
Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011
Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,
Low-dose Naltrexone (LDN) Fact Sheet 2015
PO Box 1083, Buxton Norwic NR10 5WY Telephone: +44 1603 279 014 Email: contact@ldnresearchtrust.org Web: www.ldnresearhctrust.org www.ldnaware.org Contact: Linda Elesgood Low-dose Naltrexone (LDN) Fact
Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
Survey of 267 Patients Using Low Dose Naltrexone for Multiple Sclerosis
Survey of 267 Patients Using Low Dose Naltrexone for Multiple Sclerosis Summary In order to stimulate interest among other academic researchers in LDN trials for MS, an online patient tracking system has
Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
The Immunopathogenesis of Relapsing MS
The Immunopathogenesis of Relapsing MS Olaf Stüve, M.D., Ph.D. Neurology Section VA North Texas Health Care System Dallas VA Medical Center Departments of Neurology and Neurotherapeutics University of
placebo-controlledcontrolled double-blind, blind,
Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which
Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study Nele Claes 1 *; Tessa Dhaeze 1 *; Judith Fraussen PhD 1 ; Bieke Broux
OHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
Programa Cooperación Farma-Biotech Neurociencias NT-KO-003
Programa Cooperación Farma-Biotech Neurociencias NT-KO-003 A new oral treatment for Multiple Sclerosis based on a novel mechanism of action Barcelona, 15 de febrero 2011 Programa Cooperación Farma-Biotech
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis
Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple
Chapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
Focus on CNS Drug Development Treating secondary progressive multiple sclerosis. Simon Wilkinson, CEO
Focus on CNS Drug Development Treating secondary progressive multiple sclerosis Simon Wilkinson, CEO Forward Looking Statements 2 This Presentation (and any financial information that may be provided by
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
Electrohypersensitivity and multiple chemical sensitivity: two clinicbiological. disorder?
5 th Paris Appeal Congress, 18th of May, 2015 Royal Academy of Medicine, Belgium IDIOPATHIC ENVIRONMENTAL INTOLERANCE: WHAT ROLE FOR ELECTROMAGNETIC FIELDS AND CHEMICALS? Electrohypersensitivity and multiple
Disease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model
Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Robyn Balden & Farida Sohrabji Texas A&M Health Science Center- College of Medicine ISC
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for
Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004
Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
Clin Rheumatol (2014) 33:451 459 DOI 10.1007/s10067-014-2517-2 REVIEW ARTICLE The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain Jarred Younger & Luke Parkitny
Low-dose Naltrexone (LDN) Fact Sheet 2015
Low-dose Naltrexone (LDN) Fact Sheet 2015 Naltrexone is a class of drug known as an opiate antagonist. Its normal use is in treating addiction to opiate drugs such as heroin or morphine. The dose used
Restless Legs Syndrome: Sequential Treatment with Rifaximin and Low Dose Naltrexone
Restless Legs Syndrome: Sequential Treatment with Rifaximin and Low Dose Naltrexone Trisha Myers, PA-C, Leonard Weinstock, MD, Arthur Walters, MD Abstract Background: Restless legs syndrome (RLS) has been
Reversibility of Acute Demyelinating Lesions in relapsingremitting
Reversibility of Acute Demyelinating Lesions in relapsingremitting Multiple Sclerosis Omar A. Khan ( Division of Neuroimmunology, Department of Neurology, Neurology and Research Services. Veterans Affairs
FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September
Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report
Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical
Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD
Treatment in Relapsing MS: Choosing Among the Options Donald Negroski, MD Disclosures Research Grants Educational activities and lectures Consulting or other services including Continuing Medical Education
Clinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION
MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION Michael K. Racke, MD Professor and Chairman in Neurology The Helen C. Kurtz Chair in Neurology Department of Neurology Ohio State University
Disease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
Committee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
Targeting brain inflammation to treat methamphetamine addiction
Targeting brain inflammation to treat methamphetamine addiction Keith Heinzerling MD MPH UCLA Center for Behavioral and Addiction Medicine UCLA Department of Family Medicine October 23, 2014 Advancing
Laquinimod Polman, C. et al. Neurology 2005;64:987-991
Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks
Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
March 30, 2007. I. IVIg IS AN ACCEPTED THERAPY FOR RRMS, AND IS PRESCRIBED ALONG WITH A DISEASE-MODIFYING AGENT SUCH AS COPAXONE
18 Timberline Drive Farmington, CT 06032 (860) 674-1370 (phone) (860) 674-1378 (fax) (860) 305-9835 (cell) www.advocacyforpatients.org patient_advocate@sbcglobal.net AZ Benefit Options ATTN: Appeals PO
Alcohol Overuse and Abuse
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
Montelukast Sodium. -A new class of seasonal allergic rhinitis therapy
Montelukast Sodium -A new class of seasonal allergic rhinitis therapy Symptoms of Seasonal Allergic Rhinitis Nasal itch Sneezing Rhinorrhoea Nasal stuffiness Pathogenesis of Allergic Rhinitis Mast cells,
TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines
TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines DATE: 13 March 2013 CONTEXT AND POLICY ISSUES Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central
Senyo Agbenowu M.S Student Email: senyagbe@pharmacy.isu.edu Advisor: Dr. Daniels My research interest is studying the role of histone deacetylases
Senyo Agbenowu M.S Student Email: senyagbe@pharmacy.isu.edu Advisor: Dr. Daniels My research interest is studying the role of histone deacetylases (HDAC) in Dexamethasone resistance in Interleukin 6 (IL6)
9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance
Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical
Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
SYNTHETIC BIOLOGICS (NYSE-MKT: SYN)
UPDATE REPORT Biotechnology Industry June 26, 2013 SYNTHETIC BIOLOGICS (NYSE-MKT: SYN) Introducing a New Therapy for Multiple Sclerosis KEITH A. MARKEY, PH.D., M.B.A. 212-514-7914 KMARKEY@GRIFFINSECURITIES.COM
Bioshares Investment Summit Presentation
ABN 16 165 160 841 ASX RELEASE 20 JULY 2015 Bioshares Investment Summit Presentation Innate Immunotherapeutics' CEO Mr. Simon Wilkinson gave a presentation (attached) at the 2015 Bioshares Investment Summit
- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -
PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with
STROKE CARE NOW NETWORK CONFERENCE MAY 22, 2014
STROKE CARE NOW NETWORK CONFERENCE MAY 22, 2014 Rehabilitation Innovations in Post- Stroke Recovery Madhav Bhat, MD Fort Wayne Neurological Center DISCLOSURE Paid speaker for TEVA Neuroscience Program.
The Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central
The Prospect of Stem Cell Therapy in Multiple Sclerosis Multiple sclerosis is a multifocal inflammatory disease of the central nervous system that generally affects young individuals, causing paralysis
Psychology 3625 Cellular and Molecular Neuroscience. Dr Darren Hannesson
Psychology 3625 Cellular and Molecular Neuroscience Dr Darren Hannesson Lecture 6 Cells of the nervous system Neurons Glia Other cell types Blood-brain barrier Types of nervous system cells Neurons The
NUVIGIL (armodafinil) oral tablet
NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based
J.P. Morgan Cazenove Therapeutic Seminar
Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private
Management in the pre-hospital setting
Management in the pre-hospital setting Inflammation of the joints Two main types: Osteoarthritis - cartilage loss from wear and tear Rheumatoid arthritis - autoimmune disorder Affects all age groups,
A Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
Performance Improvement Strategies in Multiple Sclerosis. Community of Practice Audioconference Recorded December 7, 2010
Performance Improvement Strategies in Multiple Sclerosis Community of Practice Audioconference Recorded December 7, 2010 Audioconference faculty: Bruce A. Cohen, MD Director, Multiple Sclerosis Program
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,
Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre
Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability
ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
Department of Pathology, The University of Iowa, Iowa City, USA (YP Agrawal, MD PhD)
1 Low dose naltrexone therapy in multiple sclerosis Y.P. Agrawal Department of Pathology, The University of Iowa, Iowa City, USA (YP Agrawal, MD PhD) Correspondence to: Yash Pal Agrawal, MD PhD, Department
Policy #: 457 Latest Review Date: December 2010
Effective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Naltrexone (Vivitrol ) Injections Policy #: 457 Latest Review
Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy
Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health
ACUPUNCTURE AND MULTIPLE SCLEROSIS
ACUPUNCTURE AND MULTIPLE SCLEROSIS About multiple sclerosis Around 100,000 people in the UK have multiple sclerosis (MS) (MS Society 2012), an autoimmune disorder of the central nervous system (Compston
The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
Dr Le Dinh Thi Neurology Department
Dr Le Dinh Thi Neurology Department Summary Multiplesclerosis(MS)is considered anautoimmune disease associated with immune activity against central nervous system antigens Immunosuppression and immuno-modulation
Natural Modality in the Treatment of Primary Headaches. William S. Mihin, D.C. Catharine Helms, M.S. Michelle M. Anderson, M.S.N., F.N.P.
Natural Modality in the Treatment of Primary Headaches William S. Mihin, D.C. Catharine Helms, M.S. Michelle M. Anderson, M.S.N., F.N.P. Abstract Headaches are both a prevalent and disabling condition.
New Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
AUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
Clinical and Therapeutic Cannabis Information. Written by Cannabis Training University (CTU) All rights reserved
Clinical and Therapeutic Cannabis Information Written by Cannabis Training University (CTU) All rights reserved Contents Introduction... 3 Chronic Pain... 6 Neuropathic Pain... 8 Movement Disorders...
Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
Understanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS
News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active
AUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
A blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy
Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmad G. Hegazi, Khaled Al- Menabbawy, Eman H. Abd El- Rahman and Suzette I. Helal National Research Center, Dokki, Giza, Egypt
Case Report Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
Case Reports in Medicine Volume 2012, Article ID 134636, 4 pages doi:10.1155/2012/134636 Case Report Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis Lei Liu and Fiona
FIFTH BIENNIAL CONFERENCE ON RESTING STATE BRAIN CONNECTIVITY 2016 VIENNA
FIFTH BIENNIAL CONFERENCE ON SEPTEMBER 21 23/2016 Technical advances and methodological issues in measuring functional and structural brain connectivity: multimodal human imaging methods, animal models,
Calendar of events NEUROLOGY
Calendar of events 2016 NEUROLOGY Rome, Italy 29 January 2016 Updates on MS treatment management Project an individualized treatment plan in MS Explain how to manage patients day to day issues List the
Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
5.07.04. Provigil Nuvigil. Provigil (modafinil) / Nuvigil (armodafinil) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.04 Subject: Provigil Nuvigil Page: 1 of 6 Last Review Date: June 19, 2015 Provigil Nuvigil Description
Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis
May 25, 2015 Contact: Shikha Virdi 905-919-0200 ext. 5504 Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis Rebif now reimbursed under Ontario Drug Benefit Program
Sensitive and reproducible clinical rating
CLINICAL AND MRI MARKERS OF MS DISEASE PROGRESSION * Richard A. Rudick, MD ABSTRACT Sensitive and reproducible measures of multiple sclerosis (MS) severity and progression are important in the treatment
Acute & Chronic Pain Management (requiring opioid analgesics) in Patients Receiving Pharmacotherapy for Opioid Addiction
Acute & Chronic Pain Management (requiring opioid analgesics) in Patients Receiving Pharmacotherapy for Opioid Addiction June 9, 2011 Tufts Health Care Institute Program on Opioid Risk Management Daniel
NEALS Clinical Trials (Studies 1-5)
NEALS and NCRI Sample Repository Request Form Instructions & Descriptions The sample repository consists of serum, plasma, cerebrospinal fluid (CSF), urine, extracted DNA and whole blood samples from NEALS
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
Recent Multiple Sclerosis (MS)
neuroscience Promoting Remyelination and Preventing Demyelination New Research Goals in Finding a Therapy for Multiple Sclerosis Priya Rajgopal 11 24 Recent Multiple Sclerosis (MS) research has made it
Understanding the Pain Trajectory During Treadmill Testing in Peripheral Artery Disease
Understanding the Pain Trajectory During Treadmill Testing in Peripheral Artery Disease Diane Treat-Jacobson, PhD, RN, FAHA, FAAN Susan J. Henly, PhD, RN Ulf G. Bronas, PhD, ATC, ATR Arthur S. Leon, MD,
Nora D. Volkow, M.D. Director National Institute on Drug Abuse
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine Replacement Therapies (NRT) Bupropion Varenicline For Alcoholism Disulfiram
FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from three Phase III studies of the
Media Release Basel, 12 April 2016 Roche to present new data at AAN showing superior efficacy of investigational medicine ocrelizumab versus comparators on disease activity and progression in two forms
Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
Department of Neurology and Neurosurgery Clinical and Clinical Research Fellowship Application Form
Department of Neurology and Neurosurgery Clinical and Clinical Research Fellowship Application Form Fellowship in Multiple Sclerosis and Neuroinflammatory Disorders Type of Fellowship: Clinical Research
Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15
PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man
MEDICAL POLICY HIGH-DOSE CHEMOTHERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL RESCUE FOR AUTOIMMUNE DISEASES, INCLUDING MULTIPLE SCLEROSIS MP-9.
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): Effective Date: June 17, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND High dose chemotherapy (HDC) involves the